Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/67707
DC FieldValueLanguage
dc.contributor.authorLin, C.en_US
dc.contributor.authorChen, D.R.en_US
dc.contributor.authorChang, K.J.en_US
dc.contributor.authorChang, T.W.en_US
dc.contributor.authorWang, H.C.en_US
dc.date2012zh_TW
dc.date.accessioned2014-06-11T05:55:33Z-
dc.date.available2014-06-11T05:55:33Z-
dc.identifier.issn0344-5704zh_TW
dc.identifier.urihttp://hdl.handle.net/11455/67707-
dc.description.abstractPreclinical data indicate that the combination of docetaxel, cisplatin and trastuzumab (TCH) may have the potential for clinically significant activity against breast cancers that overexpress the her2/neu gene (HER2). An open-label phase II trial was designed to investigate the response rate and toxicity profile of TCH in breast cancer patients with a primary tumor 2-5 cm in diameter (T2) in its original size. Thirty breast cancer patients with HER2-overexpressing tumors were enrolled. Patients received 6 cycles of docetaxel at 60 mg/m(2) and cisplatin at 50 mg/m(2) given on day 1 and then every 21 days. Trastuzumab was given on day 1, cycle 1 (4 mg/kg), and then continued weekly at 2 mg/kg for 1 year or until disease progression. Tumor measurements were obtained at baseline as well as after 3 and 6 cycles of chemotherapy. We identified 29 breast cancer patients in Taiwan, of whom 13 (44.8%) had pathological complete responses. No cardiac toxicity was observed. Hematologic grade 4 or 3 toxicities were observed in 1 of 28 patients. Non-hematologic grade 4 or 3 toxicities with a reverse pattern were observed in 6 of 29 patients. The results of our study indicate that TCH neoadjuvant chemotherapy is feasible and active in T2 HER2-overexpressing breast cancer patients in terms of pathological complete response rate, complete response, partial response and manageable toxicities.en_US
dc.language.isoen_USzh_TW
dc.relationCancer Chemotherapy and Pharmacologyen_US
dc.relation.ispartofseriesCancer Chemotherapy and Pharmacology, Volume 69, Issue 5, Page(s) 1363-1368.en_US
dc.relation.urihttp://dx.doi.org/10.1007/s00280-012-1841-yen_US
dc.subjectBreast canceren_US
dc.subjectHER2en_US
dc.subjectDocetaxelen_US
dc.subjectCisplatinen_US
dc.subjectTrastuzumaben_US
dc.subjectpathological complete responseen_US
dc.subjecttherapyen_US
dc.subjecttrialen_US
dc.subjectreceptoren_US
dc.subjectpaclitaxelen_US
dc.subjectcarcinomaen_US
dc.subjectadjuvanten_US
dc.subjectwomenen_US
dc.subjectherceptinen_US
dc.subjectsurvivalen_US
dc.titleA phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancersen_US
dc.typeJournal Articlezh_TW
dc.identifier.doi10.1007/s00280-012-1841-yzh_TW
Appears in Collections:期刊論文
文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.